Latent autoimmune diabetes in adults
diseaseOn this page
Summary
Latent autoimmune diabetes in adults (MONDO:0850306) is a disease and 5 clinical trials. Top therapeutic interventions include cholecalciferol and cofrogliptin. A subtype of type 1 diabetes mellitus — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 5
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | latent autoimmune diabetes in adults |
| Mondo ID | MONDO:0850306 |
| DOID | DOID:0080846 |
| ICD-11 | 1918279014 |
| UMLS | C1739108 |
| MedGen | 895261 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of type 1 diabetes mellitus. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › endocrine system disorder › autoimmune disorder of endocrine system › type 1 diabetes mellitus › latent autoimmune diabetes in adults
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 5.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04262479 | PHASE2 | COMPLETED | Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes |
| NCT06941675 | Not specified | RECRUITING | Hybrid Closed-Loop System in LADA Patients: A Randomized Trial |
| NCT07460336 | Not specified | NOT_YET_RECRUITING | Effects of Cofrogliptin on Beta-Cell Function in LADA Patients |
| NCT06098729 | Not specified | COMPLETED | Digital Exercise for Middle-Aged Adults With Type 1 Diabetes and Other Absolute Insulin Deficiency Diabetes |
| NCT06167616 | Not specified | COMPLETED | Infections and Latent Autoimmune Diabetes in Adults |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CHOLECALCIFEROL | 4 | 2 |
| COFROGLIPTIN | 2 | 1 |
Related Atlas pages
- Drugs: Cholecalciferol